CORT Revenue of $256.1 million, a 32 percent increase over the same period in 2025 Korlym® and authorized generic product revenue of $20
CORT Revenue of $256.1 million, a 32 percent increase over the same period in 2025 Korlym® and authorized generic product revenue of $208.6 million Lifyorli™ product revenue of $47.6 million Increase in 2026 revenue guidance to $1.1 — $1.2 billion Net income of $43.0 million, compared to $35.1 million in seco